Renal clearable CRISPR nanosensor targeting mitochondrial DNA mutation for noninvasive monitoring of tumor progression and metastasis
Science Advances · 21.11.2025 · 11 (47)
DOI: 10.1126/sciadv.adz4594 ↗Kurz gefasst
Fachartikel in der Zeitschrift Science Advances, erschienen am 21.11.2025. Verfasst von Yanan Li und 11 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmaceutical Sciences, State Key Laboratory of Metabolic Dysregulation and Prevention and Treatment of Esophageal Cancer, State Key Labor…. Hauptthemen laut MEDLINE: DNA, Mitochondrial, Biomarkers, Tumor, Biosensing Techniques, Cell-Free Nucleic Acids. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 76 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: National Natural Science Foundation of China, Young Scientists Fund of the National Natural Science Foundation of China, Science and Technology Project of Henan Province.
Abstract (Originalsprache)
Mitochondrial DNA (mtDNA) mutations are emerging as important molecular features of tumorigenesis. Liquid biopsies, involving analysis of cell-free mtDNA, enable early cancer detection but suffer from low sensitivity due to scarce analytes. Here, we developed a CRISPR/Cas12a-mediated urinary biomarker, termed CasUber, for in vivo monitoring of tumor progression and metastasis. Our results demonstrate that CasUber can deliver a CRISPR detection system into tumor cell mitochondria, leverage the single-nucleotide variant recognition ability and trans-cleavage activity of Cas12a to convert tumor-specific mtDNA mutations into renal-clearable fluorescent biomarkers, and exocytosed along with the natural efflux pathway of damaged mtDNA. As a result, CasUber enables discrimination of ultrasmall tumor lesions (~1 cubic millimeter) and detection of lung tumor nodules earlier than bioluminescence imaging in a blood-lung metastasis model. This renal clearable nanosensor allows in situ recognition of specific gene mutation to generate amplified signals, overcoming the limitation of low mtDNA abundance and enabling noninvasive and ultrasensitive monitoring of tumor progression and metastasis via a simple urine test.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- School of Pharmaceutical Sciences, State Key Laboratory of Metabolic Dysregulation and Prevention and Treatment of Esophageal Cancer, State Key Laboratory of Antiviral Drugs, Tianjian Laboratory of Advanced Biomedical S…
- Department of Pathogen Biology, School of Basic Medical Sciences, Zhengzhou University, Zhengzhou 450001, China.
- Beijing Life Science Academy, Beijing 102209, China.
ORCID-Profile: Yanan Li, Yonghua Wu, Ru Xu, Hua Gao, Kaixiang Zhang
Förderung
- National Natural Science Foundation of China
- Young Scientists Fund of the National Natural Science Foundation of China
- Science and Technology Project of Henan Province
- Henan Province Fund for Cultivating Advantageous Disciplines
Zitieren
APA
Li, Y., Wu, Y., Zheng, Z., Wu, Y., Zhang, Y., Zhang, J., Quan, F., Zhao, W., Xu, R., Li, Y., Gao, H., & Zhang, K. (2025). Renal clearable CRISPR nanosensor targeting mitochondrial DNA mutation for noninvasive monitoring of tumor progression and metastasis. Science Advances, 11(47). https://doi.org/10.1126/sciadv.adz4594
Vancouver
Li Y, Wu Y, Zheng Z, Wu Y, Zhang Y, Zhang J, et al. Renal clearable CRISPR nanosensor targeting mitochondrial DNA mutation for noninvasive monitoring of tumor progression and metastasis. Science Advances. 2025;11(47). doi:10.1126/sciadv.adz4594
BibTeX
@article{Li2025,
author = {Li, Yanan and Wu, Yonghua and Zheng, Ziyue and Wu, Yige and Zhang, Yongyuan and Zhang, Jingjing and Quan, Fenglei and Zhao, Wen and Xu, Ru and Li, Yiwei and Gao, Hua and Zhang, Kaixiang},
title = {Renal clearable CRISPR nanosensor targeting mitochondrial DNA mutation for noninvasive monitoring of tumor progression and metastasis},
journal = {Science Advances},
year = {2025},
volume = {11},
number = {47},
doi = {10.1126/sciadv.adz4594}
}
EUVIMED